Santiago Escrivá-de-Romaní

9PUBLICATIONS
82CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Dec 03, 2025
Palbociclib, Trastuzumab, and Endocrine Therapy in Pretreated HER2-Positive and PAM50 Luminal Advanced Breast Cancer: Randomized Phase II, SOLTI-1303 PATRICIA Trial.

Eva Ciruelos, Tomás Pascual, Guillermo Villacampa

|Dec 01, 2025
Associations of the HER2DX Genomic Test with Biological and Pathologic Features in HER2-Positive Breast Cancer.

Esther Sanfeliu, Anabel Martínez-Romero, Mercedes Marín-Aguilera

|Jan 08, 2023
Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Current and Future Trends.

Kreina Sharela Vega Cano, David Humberto Marmolejo Castañeda, Santiago Escrivá-de-Romaní

|Dec 08, 2022
Clearance of ctDNA in triple-negative and HER2-positive breast cancer patients during neoadjuvant treatment is correlated with pathologic complete response.

Nikaoly Ciriaco, Esther Zamora, Santiago Escrivá-de-Romaní

|Oct 12, 2022
Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody-Drug Conjugates in Breast Cancer.

Santiago Duro-Sánchez, Mercedes Nadal-Serrano, Marta Lalinde-Gutiérrez

|Dec 01, 2020
Trastuzumab Emtansine Plus Non-Pegylated Liposomal Doxorubicin in HER2-Positive Metastatic Breast Cancer (Thelma): A Single-Arm, Multicenter, Phase Ib Trial.

Elena López-Miranda, José Manuel Pérez-García, Serena Di Cosimo

Pageof 2

Frequent Collaborators

5 joint publications

Javier Cortés

4 joint publications

Noelia Martínez

4 joint publications

Cristina Saura

3 joint publications

Mafalda Oliveira